# US 9,040,244 B2 · HIV-1 genotyping assay for global surveillance of HIV-1 drug resistance > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,040,244 B2 - Document ID: US9040244B2 - Status: Granted - Kind: B2 - Application number: 14/125,564 - Filed: 2012-07-05 - Published: 2014-04-17 - Granted: 2015-05-26 - Earliest claimed: 2011-07-05 - Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention - Applicants: Chunfu Yang; Zhiyong Zhou; Nicholas Wagar; Joshua R. DeVos - Inventors: Chunfu Yang; Zhiyong Zhou; Nicholas Wagar; Joshua R. DeVos - Web page: https://patentgrep.com/patent/US9040244B2 ## CPC - C12Q 1/703: {Viruses associated with AIDS} - C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism - C12Q 2600/156: Polymorphic or mutational markers - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES ## Abstract Provided herein are new methods, primers, and kits for genotyping HIV-1, including group M viral strains. The methods can be used for HIV-1 drug resistance surveillance and monitoring, for example in resource-poor countries. The disclosed methods can detected more mixed HIV-1 population than previous methods. Given the high efficiency in genotyping diverse HIV-1 group M viral strains from plasma and dried blood spot (DBS) samples and substantial reagent cost saving, the disclosed methods can be used for HIV-1 drug resistance genotyping in both antiretroviral therapy (ART)-naive and -experienced populations for surveillance purposes and patient monitoring. ## Claims ### Claim 1 A method of genotyping HIV-1 in a sample, comprising: (a) contacting a sample obtained from a subject with a first forward nucleic acid primer comprising a mixture of SEQ ID NO: 1 and 2 and a first reverse nucleic acid primer consisting of SEQ ID NO: 4, or contacting the sample obtained from a subject with a first forward nucleic acid primer consisting of SEQ ID NO: 3 and a first reverse nucleic acid primer consisting of SEQ ID NO: 4, thereby generating a first reaction mixture; (b) incubating the first reaction mixture under conditions sufficient to amplify by polymerase chain reaction (PCR) a portion of HIV-1 pol in the first reaction mixture, thereby generating a first amplification product; (c) contacting the first amplification product with a second forward nucleic acid primer consisting of SEQ ID NO: 5 and a second reverse nucleic acid primer consisting of SEQ ID NO: 6, thereby generating a second reaction mixture; (d) incubating the second reaction mixture under conditions sufficient to amplify by PCR a portion of HIV-1 pol comprising HIV-1 reverse transcriptase (RT) and HIV-1 protease (PR) in the second reaction mixture, thereby generating a second amplification product; and (e) sequencing the first amplification product and the second amplification product to determine the genotype of HIV-1, or subjecting the first amplification product and the second amplification product to allele-specific analysis to determine the genotype of HIV-1, wherein the method can detect a viral load of ≧1,000 copies/ml. ### Claim 2 (depends on 1) The method of claim 1, wherein, incubating the first reaction mixture under conditions sufficient to amplify by PCR a portion of HIV-1 pol in the first reaction mixture comprises performing reverse transcription polymerase chain reaction (RT-PCR) on the first reaction mixture, thereby generating an RT-PCR product as the first amplification product; incubating the second reaction mixture under conditions sufficient to amplify by PCR a portion of HIV-1 pol comprising HIV-1 RT and HIV-1 PR in the second reaction mixture comprises performing nested PCR on the second reaction mixture, thereby generating a nested PCR product as the second amplification product; and sequencing the first amplification product comprises sequencing the RT-PCR product or sequencing the second amplification product comprises sequencing the nested PCR product. ### Claim 3 (depends on 2) The method of claim 2, wherein the sequencing the RT-PCR product or nested PCR product comprises contacting the RT-PCR product or nested PCR product with a nucleic acid primer comprising SEQ ID NO: 5, 6, 7, 8, 9, or 10. ### Claim 4 (depends on 1) The method of claim 1, further comprising comparing the genotype of HIV-1 to the WHO surveillance drug resistance mutation (SDRM) list or International AIDS Society (IAS) HIV drug resistance mutation list. ### Claim 5 (depends on 1) The method of claim 1, further comprising obtaining RNA from the sample prior to contacting the sample with the first and second nucleic acid primers. ### Claim 6 (depends on 1) The method of claim 1, further comprising purifying the first amplification product or the second amplification product prior to sequencing the first amplification product and the second amplification product or subjecting the first amplification product and the second amplification product to allele-specific analysis. ### Claim 7 (depends on 1) The method of claim 1, wherein the HIV-1 genotype is a drug resistant mutation in an HIV protease protein comprising a substitution shown in Table 1. ### Claim 8 (depends on 1) The method of claim 1, wherein the HIV-1 genotype is a drug resistant mutation in an HIV reverse transcriptase protein comprising a substitution shown in Table 2. ### Claim 9 (depends on 1) The method of claim 1, wherein the method has a specificity of at least 99%. ### Claim 10 (depends on 1) The method of claim 1, wherein the method has a sensitivity of at least 95%. ### Claim 11 (depends on 1) The method of claim 1, wherein the method can genotype HIV-1 of any subtype and circulating recombinant forms (CRFs) and unique recombinant forms (URFs) of group M. ### Claim 12 (depends on 1) The method of claim 1, wherein the sample is a blood sample or fraction thereof. ### Claim 13 (depends on 12) The method of claim 12, wherein the blood sample is a dried blood spot. ### Claim 14 (depends on 1) The method of claim 1, wherein the subject is known or suspected of being infected with HIV-1. ### Claim 15 (depends on 1) The method of claim 1, wherein the subject has been treated with one or more antiretroviral drugs (ARVs). ### Claim 16 (depends on 1) The method of claim 1, wherein genotyping HIV-1 permits detection of a new drug resistant HIV-1 mutation. ### Claim 17 (depends on 1) The method of claim 1, wherein the subject is a human subject. ### Claim 18 (depends on 1) The method of claim 1, further comprising determining the HIV-1 viral load of the subject.